Table 2 STING agonists in clinical trials
From: cGAS-STING, an important pathway in cancer immunotherapy
Agent | Target | Cancer type | Phase | Clinicaltrial ID |
|---|---|---|---|---|
ADU-S100(MIW815) | STING | Head and neck cancer | Phase 2 | NCT03937141 |
ADU-S100(MIW815)+/− Ipilimumab | STING+/− CTLA-4 | Solid tumors/lymphomas | Phase 1 | NCT02675439 |
ADU-S100(MIW815) + PDR001 | STING+PD-1 | Solid tumors/lymphomas | Phase 1 | NCT03172936 |
E7766 | STING | Urinary bladder neoplasms | Phase 1 | NCT04109092 |
E7766 | STING | Lymphoma/advanced solid tumors | Phase 1 | NCT04144140 |
GSK3745417 | STING | Neoplasms | Phase 1 | NCT03843359 |
MK-1454 | STING | Solid tumors/lymphomas | Phase 1 | NCT03010176 |
MK-1454 + pembrolizumab | STING+PD-1 | Head and neck squamous cell carcinoma | Phase 2 | NCT04220866 |
BMS-986301 | STING | Solid cancers | Phase 1 | NCT03956680 |
SB 11285 | STING | Solid tumor | Phase 1 | NCT04096638 |